A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Nulabeglogene autogedtemcel (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacogenomic; Proof of concept; Therapeutic Use
- Acronyms RESTORE
- Sponsors Kamau Therapeutics
- 21 Mar 2024 According to a LENZ Therapeutics media release, LENZ Therapeutics has merged with Graphite Bio to form LENZ Therapeutics.
- 31 Jan 2024 Planned End Date changed from 1 May 2026 to 31 Jul 2027.
- 31 Jan 2024 Planned primary completion date changed from 1 May 2026 to 31 Jul 2026.